검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Kymriah (tisagenlecleucel) | Brentuximab Vedotin | Polatuzumab Vedotin | Zanubrutinib | Acalabrutinib |
Overview Company | Novartis | Seagen / Takeda | Roche / Genentech | Juan P. Alderuccio, MD | Epizyme, Inc. |
Overview Modality | CGT | ADC | ADC | ANTIBODY | ADC |
Overview Target | CD19 | Hodgkin Disease | FRα | CNS Lymphoma | Diffuse Large B-Cell Lymphoma |
Overview Indication | ALL, DLBCL, FL | Hodgkin Lymphoma | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | CNS Lymphoma | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 | PHASE_2 |
Overview Status | APPROVED | ACTIVE | RECRUITING | RECRUITING | RECRUITING |
MoA Mechanism | CD19-directed CAR T killing | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | inhibits B-cell receptor signaling | inhibits B-cell receptor signaling |
MoA Biomarker | CD19 | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic | CD20 expression | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with rel |
PK/PD Half-life | — | — | 12.2 h | — | — |
PK/PD Species | NHP, While of great clinical benefit | Mouse | Rat, 048) | Rat | Mouse |
PK/PD Animal (cat.) | NHP, In vitro | Mouse, In vitro | Rat | Rat | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | PD | pharmacokinetic | PK | Pharmacokinetic |
Toxicology Species | NHP, Mouse, While of great clinical benefit | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse, Rat, 048) | Rat | Mouse, Rat |
Toxicology Animal (cat.) | Mouse | Mouse, Rat, NHP | Mouse, Rat, NHP | Rat | Rat |
Toxicology Major finding | thrombocytopenia (27%) among 52 responding patients | Hepatotoxicity : Monitor liver enzymes and bilirubin ( 5 | Hepatotoxicity: Monitor liver enzymes and bilirubin | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor hepatic function throughout t | Hepatotoxicity, Including Drug Induced Liver Injury: Monitor hepatic function throughout tr |
Toxicology CRS | 77% | — | — | — | — |
Clinical Primary efficacy | — | ORR 86% | ORR 95% | ORR 95.2% | ORR 82.4% |
Clinical ORR | — | 86% | 95.0% | 95.2% | 82.4% |
Clinical PFS | — | — | — | 61.4 | NA |
Clinical OS | 0 | — | — | NA | NA |
Clinical Result source | ClinicalTrials.gov NCT04225676 | ClinicalTrials.gov NCT01712490 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT02343120 | ClinicalTrials.gov NCT03932331 |
Clinical Data Tier / Score | C · 69 | A · 89 | S · 92 | B · 78 | C · 71 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 | PHASE_2 |
Clinical Dose / schedule | Single infusion | — | — | — | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 5개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |||||
|---|---|---|---|---|---|
Overview Program | Kymriah (tisagenlecleucel) | Brentuximab Vedotin | Polatuzumab Vedotin | Zanubrutinib | Acalabrutinib |
Overview Company | Novartis | Seagen / Takeda | Roche / Genentech | Juan P. Alderuccio, MD | Epizyme, Inc. |
Overview Modality | CGT | ADC | ADC | ANTIBODY | ADC |
Overview Target | CD19 | Hodgkin Disease | FRα | CNS Lymphoma | Diffuse Large B-Cell Lymphoma |
Overview Indication | ALL, DLBCL, FL | Hodgkin Lymphoma | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | CNS Lymphoma | Relapsed Hematologic Malignancy; Refractory Hematologic Malignancy |
Overview Phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 | PHASE_2 |
Overview Status | APPROVED | ACTIVE | RECRUITING | RECRUITING | RECRUITING |
MoA Mechanism | CD19-directed CAR T killing | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | targeting specific cell surface antigens, many ADCs have also been associated with unique toxicities related to the antigen | inhibits B-cell receptor signaling | inhibits B-cell receptor signaling |
MoA Biomarker | CD19 | biomarker-driven treatment in NHL, including resistance mechanisms, toxicity management, optimal therapeutic | CD20 expression | biomarker to guide treatment duration in two prospective trials of venetoclax- and sonrotoclax-based triplets | biomarkers and inhibited the B-cell receptor pathway signaling in longitudinal samples from patients with rel |
PK/PD Half-life | — | — | 12.2 h | — | — |
PK/PD Species | NHP, While of great clinical benefit | Mouse | Rat, 048) | Rat | Mouse |
PK/PD Animal (cat.) | NHP, In vitro | Mouse, In vitro | Rat | Rat | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic | PD | pharmacokinetic | PK | Pharmacokinetic |
Toxicology Species | NHP, Mouse, While of great clinical benefit | Cynomolgus monkey, Mouse, Rat | Cynomolgus monkey, Mouse, Rat, 048) | Rat | Mouse, Rat |
Toxicology Animal (cat.) | Mouse | Mouse, Rat, NHP | Mouse, Rat, NHP | Rat | Rat |
Toxicology Major finding | thrombocytopenia (27%) among 52 responding patients | Hepatotoxicity : Monitor liver enzymes and bilirubin ( 5 | Hepatotoxicity: Monitor liver enzymes and bilirubin | Hepatotoxicity, Including Drug-Induced Liver Injury : Monitor hepatic function throughout t | Hepatotoxicity, Including Drug Induced Liver Injury: Monitor hepatic function throughout tr |
Toxicology CRS | 77% | — | — | — | — |
Clinical Primary efficacy | — | ORR 86% | ORR 95% | ORR 95.2% | ORR 82.4% |
Clinical ORR | — | 86% | 95.0% | 95.2% | 82.4% |
Clinical PFS | — | — | — | 61.4 | NA |
Clinical OS | 0 | — | — | NA | NA |
Clinical Result source | ClinicalTrials.gov NCT04225676 | ClinicalTrials.gov NCT01712490 | ClinicalTrials.gov NCT03677141 | ClinicalTrials.gov NCT02343120 | ClinicalTrials.gov NCT03932331 |
Clinical Data Tier / Score | C · 69 | A · 89 | S · 92 | B · 78 | C · 71 |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 | PHASE_3 | PHASE_2 |
Clinical Dose / schedule | Single infusion | — | — | — | — |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 4일 (9일 전) | 2026년 7월 8일 (6일 전) | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교